OptiNose Story

<div class='circular--portrait' style='background:#800000;color: #F8F8FF;font-size:4em;'>OP</div>
OPTN -- USA Stock  

USD 4.11  0.02  0.49%

While some planning is required to successfully invest in stocks, sometimes taking bold action is just as important. Let's try to outline why this may be the case with OptiNose. What exactly are OptiNose shareholders getting in January? OptiNose is now traded for 4.73. The entity has historical hype elasticity of 0.15. The average price elasticity to hype of competition is about -0.04. The firm is estimated to increase in value after the next press release, with the price going to jump to 4.88. The latest volatility of headline impact on the company stock price is is way over 100 percent making price predictions on social media along less reliable. The price upswing on the next news is estimated to be 3.17%, whereas the daily expected return is now at 0.5%. Given the investment horizon of 30 days the next estimated announcement will be in about 3 days.
Published over three weeks ago
View all stories for OptiNose | View All Stories
Is OptiNose (NASDAQ:OPTN) gaining more confidence from institutional investors?
This firm's average rating is Strong Buy from 4 analysts. We provide trade recommendations to complement the recent expert consensus on OptiNose. Our dynamic recommendation engine exercises a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time.
The successful prediction of OptiNose stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as OptiNose, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of OptiNose based on OptiNose hews, social hype, general headline patterns, and widely used predictive technical indicators. We also calculate exposure to OptiNose's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to OptiNose's related companies.

Use Technical Analysis to project OptiNose expected Price

OptiNose technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of OptiNose technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of OptiNose trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

How OptiNose utilizes its cash?

To perform a cash flow analysis of OptiNose, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash OptiNose is receiving and how much cash it distributes out in a given period. The OptiNose cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Exercise or conversion by Ramy Mahmoud of 28341 shares of OptiNose subject to Rule 16b-3

Legal trades by OptiNose insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
OptiNose insider trading alert for exercise of stock option (right to buy) by Ramy Mahmoud, President and COO, on 29th of December 2020. This event was filed by Optinose Inc with SEC on 2020-12-29. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking it down a bit more

The company reported the previous year's revenue of 43.85 M. Net Loss for the year was (100.92 M) with profit before overhead, payroll, taxes, and interest of 29.34 M.

Will OptiNose latest rise continue?

Value At Risk just dropped to -5.37, may entail upcoming price decrease. OptiNose shows above-average downside volatility for the selected time horizon. We advise investors to inspect OptiNose further and ensure that all market timing and asset allocation strategies are consistent with the estimation of OptiNose future alpha.

The Bottom Line

Whereas many other companies within the drug manufacturers?specialty & generic industry are still a little expensive, even after the recent corrections, OptiNose may offer a potential longer-term growth to institutional investors. On the whole, as of the 26th of December 2020, our primary 30 days Buy-Hold-Sell recommendation on the company is Strong Sell. However, we believe OptiNose is currently undervalued with very high probability of distress for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of OptiNose. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com